Article Text
Letter
Certolizumab use in pregnancy
Statistics from Altmetric.com
Recently, Mahadevan recalled that infliximab and adalimumab are classified by the Food and Drug Administration as pregnancy class B agents because there is no documented human toxicity (Gut 2006;55:1198–206). If the decision to continue infliximab throughout pregnancy is made, it should be avoided during the third trimester when transplacental transfer is at its greatest.1 While there are limited data on the use of adalimumab and infliximab in pregnancy, the safety and efficacy of certolizumab during pregnancy are unknown.
We report the case of …
Footnotes
▸ Competing interests: Declared (the declaration can be viewed on the Gut website at http://www.gut.bmj.com/supplemental).
Patient consent: Obtained.